{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:10:12Z","timestamp":1763554212430,"version":"3.45.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-01994-0","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T13:24:24Z","timestamp":1756387464000},"page":"1894-1907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety profile of mitomycin: signal detection and time-to-onset analysis from FDA adverse event reporting system and VigiAccess databases"],"prefix":"10.1007","volume":"47","author":[{"given":"Zhenghua","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linglu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"18","key":"1994_CR1","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2021.5469","volume":"325","author":"FB Ahmad","year":"2021","unstructured":"Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829\u201330. https:\/\/doi.org\/10.1001\/jama.2021.5469.","journal-title":"JAMA"},{"issue":"1","key":"1994_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/clinchem\/hvad202","volume":"70","author":"SM Schwartz","year":"2024","unstructured":"Schwartz SM. Epidemiology of cancer. Clin Chem. 2024;70(1):140\u20139. https:\/\/doi.org\/10.1093\/clinchem\/hvad202.","journal-title":"Clin Chem"},{"issue":"3","key":"1994_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35(3):379\u201387. https:\/\/doi.org\/10.1007\/s00345-016-1928-x.","journal-title":"World J Urol"},{"issue":"1","key":"1994_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1994_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","volume":"25","author":"B Al Hussein Al Awamlh","year":"2023","unstructured":"Al Hussein Al Awamlh B, Chang SS. Novel therapies for high-risk non-muscle invasive bladder cancer. Curr Oncol Rep. 2023;25(2):83\u201391. https:\/\/doi.org\/10.1007\/s11912-022-01350-9.","journal-title":"Curr Oncol Rep"},{"key":"1994_CR6","first-page":"946","volume":"23","author":"W Szybalski","year":"1964","unstructured":"Szybalski W, Iyer VN. Crosslinking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally \u201calkylating\u201d antibiotics. Fed Proc. 1964;23:946\u201357.","journal-title":"Fed Proc"},{"issue":"1","key":"1994_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","volume":"1","author":"J Verweij","year":"1990","unstructured":"Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs. 1990;1(1):5\u201313.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"1994_CR8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1097\/JU.0000000000002454","volume":"207","author":"GH Rosen","year":"2022","unstructured":"Rosen GH, Nallani A, Muzzey C, et al. Antegrade instillation of UGN-101 (mitomycin for pyelocalyceal solution) for low-grade upper tract urothelial carcinoma: initial clinical experience. J Urol. 2022;207(6):1302\u201311. https:\/\/doi.org\/10.1097\/JU.0000000000002454.","journal-title":"J Urol"},{"issue":"9","key":"1994_CR9","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.21037\/tau-23-69","volume":"12","author":"J Gottlieb","year":"2023","unstructured":"Gottlieb J, Linehan J, Murray KS. Advances in chemoablation in upper tract urothelial carcinoma: overview of indications and treatment patterns. Transl Androl Urol. 2023;12(9):1449\u201355. https:\/\/doi.org\/10.21037\/tau-23-69.","journal-title":"Transl Androl Urol"},{"issue":"2","key":"1994_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JU.0000000000004296","volume":"213","author":"SM Prasad","year":"2025","unstructured":"Prasad SM, Shishkov D, Mihaylov NV, et al. Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION). J Urol. 2025;213(2):205\u201316. https:\/\/doi.org\/10.1097\/JU.0000000000004296.","journal-title":"J Urol"},{"issue":"1","key":"1994_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1756-9966-30-93","volume":"30","author":"K Kadoyama","year":"2011","unstructured":"Kadoyama K, Kuwahara A, Yamamori M, et al. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res. 2011;30(1):93. https:\/\/doi.org\/10.1186\/1756-9966-30-93.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1994_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist M, Stahl M, Bate A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533\u201342. https:\/\/doi.org\/10.2165\/00002018-200023060-00004.","journal-title":"Drug Saf"},{"issue":"2\u20133","key":"1994_CR13","first-page":"77","volume":"26","author":"C Tantikul","year":"2008","unstructured":"Tantikul C, Dhana N, Jongjarearnprasert K, et al. The utility of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children. Asian Pac J Allergy Immunol. 2008;26(2\u20133):77\u201382.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"2","key":"1994_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, et al. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC Cardio Oncol. 2019;1(2):172\u20138. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.006.","journal-title":"JACC Cardio Oncol"},{"issue":"5","key":"1994_CR15","doi-asserted-by":"publisher","first-page":"qfad059","DOI":"10.1093\/sexmed\/qfad059","volume":"11","author":"YE Shin","year":"2023","unstructured":"Shin YE, Rojanasarot S, Hincapie AL, et al. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a food and drug administration adverse event reporting system analysis. Sex Med. 2023;11(5):qfad059. https:\/\/doi.org\/10.1093\/sexmed\/qfad059.","journal-title":"Sex Med."},{"key":"1994_CR16","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y, et al. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022;13:862508. https:\/\/doi.org\/10.3389\/fphar.2022.862508.","journal-title":"Front Pharmacol"},{"key":"1994_CR17","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou F, Zhu C, Lou S, et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2023;14:1320458. https:\/\/doi.org\/10.3389\/fphar.2023.1320458.","journal-title":"Front Pharmacol"},{"issue":"7581","key":"1994_CR18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/bmj.39036.666389.94","volume":"333","author":"JK Aronson","year":"2006","unstructured":"Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ. 2006;333(7581):1267\u20139. https:\/\/doi.org\/10.1136\/bmj.39036.666389.94.","journal-title":"BMJ"},{"issue":"125","key":"1994_CR19","doi-asserted-by":"publisher","first-page":"125ra31","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31. https:\/\/doi.org\/10.1126\/scitranslmed.3003377.","journal-title":"Sci Transl Med"},{"key":"1994_CR20","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902. https:\/\/doi.org\/10.3389\/fphar.2024.1338902.","journal-title":"Front Pharmacol"},{"key":"1994_CR21","doi-asserted-by":"publisher","first-page":"1561020","DOI":"10.3389\/fphar.2025.1561020","volume":"16","author":"H Hu","year":"2025","unstructured":"Hu H, Zhao Y, Mao J, et al. A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases. Front Pharmacol. 2025;16:1561020. https:\/\/doi.org\/10.3389\/fphar.2025.1561020.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1994_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1994_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1994_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1994_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001.","journal-title":"Drug Saf"},{"issue":"7","key":"1994_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"4","key":"1994_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-018-0653-5","volume":"40","author":"G Fornasier","year":"2018","unstructured":"Fornasier G, Taborelli M, Francescon S, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm. 2018;40(4):795\u2013802. https:\/\/doi.org\/10.1007\/s11096-018-0653-5.","journal-title":"Int J Clin Pharm"},{"key":"1994_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01953-9","author":"Y Ye","year":"2025","unstructured":"Ye Y, Fan B, Hu X. A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel\u2013Lindau disease: insights from the FDA adverse event reporting system database. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01953-9.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"1994_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11096-023-01678-7","volume":"46","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Jiang H, Xue L, et al. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system. Int J Clin Pharm. 2024;46(2):480\u20137. https:\/\/doi.org\/10.1007\/s11096-023-01678-7.","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"1994_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323. https:\/\/doi.org\/10.1002\/pds.1001.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1994_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13(6):387\u201394. https:\/\/doi.org\/10.1002\/pds.964.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1994_CR32","doi-asserted-by":"publisher","first-page":"1170987","DOI":"10.3389\/fphar.2023.1170987","volume":"14","author":"R Zhang","year":"2023","unstructured":"Zhang R, Gao L, Chen P, et al. Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study. Front Pharmacol. 2023;14:1170987. https:\/\/doi.org\/10.3389\/fphar.2023.1170987.","journal-title":"Front Pharmacol"},{"key":"1994_CR33","doi-asserted-by":"publisher","first-page":"1538074","DOI":"10.3389\/fphar.2025.1538074","volume":"16","author":"P Zhang","year":"2025","unstructured":"Zhang P, Chen Q, Lao J, et al. Machine learning modeling for the risk of acute kidney injury in inpatients receiving amikacin and etimicin. Front Pharmacol. 2025;16:1538074. https:\/\/doi.org\/10.3389\/fphar.2025.1538074.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1994_CR34","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.3390\/curroncol30030246","volume":"30","author":"TA Gondal","year":"2023","unstructured":"Gondal TA, Chaudhary N, Bajwa H, et al. Anal cancer: the past, present and future. Curr Oncol. 2023;30(3):3232\u201350. https:\/\/doi.org\/10.3390\/curroncol30030246.","journal-title":"Curr Oncol"},{"issue":"25\u201326","key":"1994_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4414\/smw.2009.12676","volume":"139","author":"M Ozsahin","year":"2009","unstructured":"Ozsahin M, Ugurluer G, Zouhair A. Management of transitional-cell carcinoma of the renal pelvis and ureter. Swiss Med Wkly. 2009;139(25\u201326):353\u20136. https:\/\/doi.org\/10.4414\/smw.2009.12676.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"1994_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ophtha.2012.06.066","volume":"120","author":"SC Kaufman","year":"2013","unstructured":"Kaufman SC, Jacobs DS, Lee WB, et al. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. Ophthalmology. 2013;120(1):201\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2012.06.066.","journal-title":"Ophthalmology"},{"issue":"5","key":"1994_CR37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3980\/j.issn.2222-3959.2015.05.37","volume":"8","author":"T Long","year":"2015","unstructured":"Long T, Li Z. Bare sclera resection followed by mitomycin C and\/or autograft limbus conjunctiva in the surgery for pterygium: a Meta-analysis. Int J Ophthalmol. 2015;8(5):1067\u201373. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2015.05.37.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"1994_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1517\/14740338.6.1.27","volume":"6","author":"AA Mearza","year":"2007","unstructured":"Mearza AA, Aslanides IM. Uses and complications of mitomycin C in ophthalmology. Expert Opin Drug Saf. 2007;6(1):27\u201332. https:\/\/doi.org\/10.1517\/14740338.6.1.27.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1994_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3341\/kjo.1997.11.1.15","volume":"11","author":"SM Hyung","year":"1997","unstructured":"Hyung SM, Choi MY, Kang SW. Management of chronic hypotony following trabeculectomy with mitomycin C. Korean J Ophthalmol. 1997;11(1):15\u201324. https:\/\/doi.org\/10.3341\/kjo.1997.11.1.15.","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"1994_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/2008-322X.170341","volume":"10","author":"S Shokouhi-Rad","year":"2015","unstructured":"Shokouhi-Rad S, Alizadeh R, Daneshvar R. Iatrogenic bleb formation and hypotony maculopathy following pterygium surgery with mitomycin-C. J Ophthalmic Vis Res. 2015;10(3):345\u20137. https:\/\/doi.org\/10.4103\/2008-322X.170341.","journal-title":"J Ophthalmic Vis Res"},{"issue":"5","key":"1994_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/00061198-200010000-00008","volume":"9","author":"R Sihota","year":"2000","unstructured":"Sihota R, Dada T, Gupta SD, et al. Conjunctival dysfunction and mitomycin C-induced hypotony. J Glaucoma. 2000;9(5):392\u20137. https:\/\/doi.org\/10.1097\/00061198-200010000-00008.","journal-title":"J Glaucoma"},{"issue":"2","key":"1994_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00055735-199604000-00013","volume":"7","author":"H Mietz","year":"1996","unstructured":"Mietz H. The toxicology of mitomycin C on the ciliary body. Curr Opin Ophthalmol. 1996;7(2):72\u20139. https:\/\/doi.org\/10.1097\/00055735-199604000-00013.","journal-title":"Curr Opin Ophthalmol"},{"issue":"7","key":"1994_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s004170050283","volume":"237","author":"U Schraermeyer","year":"1999","unstructured":"Schraermeyer U, Diestelhorst M, Bieker A, et al. Morphologic proof of the toxicity of mitomycin C on the ciliary body in relation to different application methods. Graefes Arch Clin Exp Ophthalmol. 1999;237(7):593\u2013600. https:\/\/doi.org\/10.1007\/s004170050283.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1994_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/joco.joco_283_23","volume":"36","author":"N Nassiri","year":"2024","unstructured":"Nassiri N, Sheibani K, Kavousnezhad S, et al. Use of mitomycin C in ophthalmic surgery. J Curr Ophthalmol. 2024;36(3):211\u201322. https:\/\/doi.org\/10.4103\/joco.joco_283_23.","journal-title":"J Curr Ophthalmol"},{"key":"1994_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40942-018-0110-6","volume":"4","author":"A Mirshahi","year":"2018","unstructured":"Mirshahi A, Lashay A, Mehrabi Bahar MR, et al. Consequences of inadvertent intravitreal mitomycin C injection. Int J Retina Vitreous. 2018;4:7. https:\/\/doi.org\/10.1186\/s40942-018-0110-6.","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"1994_CR46","doi-asserted-by":"publisher","first-page":"e471942","DOI":"10.1200\/EDBK-25-471942","volume":"45","author":"M Filon","year":"2025","unstructured":"Filon M, Schmidt B. New treatment options for non-muscle-invasive bladder cancer. Am Soc Clin Oncol Educ Book. 2025;45(2):e471942. https:\/\/doi.org\/10.1200\/EDBK-25-471942.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1994_CR47","doi-asserted-by":"publisher","first-page":"175883592093795","DOI":"10.1177\/1758835920937950","volume":"12","author":"A Kokorovic","year":"2020","unstructured":"Kokorovic A, Matin SF. UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma. Ther Adv Med Oncol. 2020;12:1758835920937950. https:\/\/doi.org\/10.1177\/1758835920937950.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"1994_CR48","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/JU.0000000000002747","volume":"208","author":"AM Stover","year":"2022","unstructured":"Stover AM, Basak R, Mueller D, et al. Minimal patient-reported side effects for a chemoablative gel (UGN-102) used as frontline treatment in adults with nonmuscle-invasive bladder cancer. J Urol. 2022;208(3):580\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000002747.","journal-title":"J Urol"},{"issue":"5","key":"1994_CR49","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1097\/JU.0000000000003185","volume":"209","author":"C Labbate","year":"2023","unstructured":"Labbate C, Woldu S, Murray K, et al. Efficacy and safety of mitomycin gel (UGN-101) as an adjuvant therapy after complete endoscopic management of upper tract urothelial carcinoma. J Urol. 2023;209(5):872\u201381. https:\/\/doi.org\/10.1097\/JU.0000000000003185.","journal-title":"J Urol"},{"issue":"5","key":"1994_CR50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.euf.2023.03.016","volume":"9","author":"KM Rose","year":"2023","unstructured":"Rose KM, Murray KS, Labbate C, et al. Mitomycin gel (UGN-101) as a kidney-sparing treatment for upper tract urothelial carcinoma in patients with imperative indications and high-grade disease. Eur Urol Focus. 2023;9(5):807\u201312. https:\/\/doi.org\/10.1016\/j.euf.2023.03.016.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"1994_CR51","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JU.0000000000003645","volume":"210","author":"SM Prasad","year":"2023","unstructured":"Prasad SM, Huang WC, Shore ND, et al. Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 +\/\u2212 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS). J Urol. 2023;210(4):619\u201329. https:\/\/doi.org\/10.1097\/JU.0000000000003645.","journal-title":"J Urol"},{"issue":"3","key":"1994_CR52","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000241684","volume":"83","author":"A Fazlioglu","year":"2009","unstructured":"Fazlioglu A, Tandogdu Z, Kurtulus FO, et al. Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant! Urol Int. 2009;83(3):362\u20133. https:\/\/doi.org\/10.1159\/000241684.","journal-title":"Urol Int"},{"issue":"6","key":"1994_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12032-025-02758-6","volume":"42","author":"IM Oskouie","year":"2025","unstructured":"Oskouie IM, Amirzargar H, Dezfuli AS, et al. Reducing the effective dosage of Mitomycin C on a high-grade bladder cancer cell line through combination with selenium nanoparticles: an in vitro study. Med Oncol. 2025;42(6):207. https:\/\/doi.org\/10.1007\/s12032-025-02758-6.","journal-title":"Med Oncol"},{"issue":"4","key":"1994_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000089179","volume":"75","author":"M Racioppi","year":"2005","unstructured":"Racioppi M, Porreca A, Foschi N, et al. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Urol Int. 2005;75(4):373\u20135. https:\/\/doi.org\/10.1159\/000089179.","journal-title":"Urol Int"},{"issue":"4","key":"1994_CR55","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/archinte.1983.00350040193029","volume":"143","author":"RW Hamner","year":"1983","unstructured":"Hamner RW, Verani R, Weinman EJ. Mitomycin-associated renal failure. Case report and review. Arch Intern Med. 1983;143(4):803\u20137.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1994_CR56","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/1097-0142(19811215)48:12<2583::aid-cncr2820481208>3.0.co;2-6","volume":"48","author":"WT Hanna","year":"1981","unstructured":"Hanna WT, Krauss S, Regester RF, et al. Renal disease after mitomycin C therapy. Cancer. 1981;48(12):2583\u20138. https:\/\/doi.org\/10.1002\/1097-0142(19811215)48:12%3c2583::aid-cncr2820481208%3e3.0.co;2-6.","journal-title":"Cancer"},{"issue":"5","key":"1994_CR57","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/PAP.0000000000000122","volume":"23","author":"ML Troxell","year":"2016","unstructured":"Troxell ML, Higgins JP, Kambham N. Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol. 2016;23(5):310\u201329. https:\/\/doi.org\/10.1097\/PAP.0000000000000122.","journal-title":"Adv Anat Pathol"},{"key":"1994_CR58","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.urology.2015.12.011","volume":"89","author":"TS Feng","year":"2016","unstructured":"Feng TS, Rusnack S, Kaminski J, et al. Appendicovesical fistula following transurethral resection of bladder tumor with mitomycin C. Urology. 2016;89:e1-2. https:\/\/doi.org\/10.1016\/j.urology.2015.12.011.","journal-title":"Urology"},{"issue":"2","key":"1994_CR59","first-page":"271","volume":"18","author":"Y Yonemura","year":"1991","unstructured":"Yonemura Y, Fujimura T, Takekawa S, et al. Treatment of gastric cancer patients with peritoneal metastasis by continuous hyperthermic peritoneal infusion with mitomycin C and cisplatin. Gan To Kagaku Ryoho. 1991;18(2):271\u20136.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"1994_CR60","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/jjco\/27.2.115","volume":"27","author":"DC Wu","year":"1997","unstructured":"Wu DC, Liu JM, Chen YM, et al. Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review. Jpn J Clin Oncol. 1997;27(2):115\u20138. https:\/\/doi.org\/10.1093\/jjco\/27.2.115.","journal-title":"Jpn J Clin Oncol."},{"issue":"6","key":"1994_CR61","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1055\/s-2005-925474","volume":"31","author":"A Zakarija","year":"2005","unstructured":"Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005;31(6):681\u201390. https:\/\/doi.org\/10.1055\/s-2005-925474.","journal-title":"Semin Thromb Hemost"},{"issue":"20","key":"1994_CR62","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","volume":"28","author":"Y Segawa","year":"2010","unstructured":"Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010;28(20):3299\u2013306. https:\/\/doi.org\/10.1200\/JCO.2009.24.7577.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1994_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0169-5002(95)00516-1","volume":"14","author":"T Urban","year":"1996","unstructured":"Urban T, Bedin A, Baud M, et al. Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer. Lung Cancer. 1996;14(1):109\u201317. https:\/\/doi.org\/10.1016\/0169-5002(95)00516-1.","journal-title":"Lung Cancer"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01994-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:08:20Z","timestamp":1763554100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01994-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01994-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All data were obtained from publicly accessible pharmacovigilance databases (FAERS and VigiAccess). Ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}